Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.
Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.